Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy

Hye Ryun Kim, Jee Hung Kim, Yumie Rhee, Hosun Lee, Seung Eun Song, Chan Kim, Sukyung Song, Sung Hoon Noh, SunYoung Rha

Research output: Contribution to journalArticle

Abstract

Objective: We performed this prospective study to identify both the incidence of adrenal insufficiency (AI) and health-related quality of life (HRQOL) in advanced gastric cancer (AGC) patients who were treated with the S-1 plus cisplatin (SP) regimen as a first-line palliative chemotherapy. Methods: We assessed adverse events (AEs) observed in 52 patients who received the SP regimen for AGC between January 2009 and June 2010 using the Common Toxicity Criteria Adverse Events (CTCAE) version 3.0. Adrenal function was assessed at baseline and 12 weeks after chemotherapy using the low-dose adrenocorticotropic hormone stimulation test. HRQOL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 (EORTC-QLQ C30). Results: The incidence of AI was 30.8% (n = 16) and of AE observed 55% (n = 29) among 52 patients after 12 weeks of chemotherapy. Of 29 patients with AE, 34.4% (n = 10) were diagnosed with AI, and of 23 patients without AE, 26.1% (n = 6) were diagnosed with AI. Conclusion: The incidence of secondary AI in AGC patients was not rare and was not correlated with the presence of nonspecific AEs. Although patients diagnosed with AI did not show any related symptoms, they are at risk of potentially life-threatening consequences. Thus, the evaluation of AI could be suggested for patients who received chemotherapy.

Original languageEnglish
Pages (from-to)248-254
Number of pages7
JournalOncology (Switzerland)
Volume90
Issue number5
DOIs
Publication statusPublished - 2016 May 1

Fingerprint

Adrenal Insufficiency
Stomach Neoplasms
Quality of Life
Drug Therapy
Cisplatin
Incidence
Adrenocorticotropic Hormone
Organizations
Prospective Studies
Research

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Hye Ryun ; Kim, Jee Hung ; Rhee, Yumie ; Lee, Hosun ; Song, Seung Eun ; Kim, Chan ; Song, Sukyung ; Noh, Sung Hoon ; Rha, SunYoung. / Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy. In: Oncology (Switzerland). 2016 ; Vol. 90, No. 5. pp. 248-254.
@article{3cfbb07589fe4a9bbaf1ece9ecaae2fc,
title = "Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy",
abstract = "Objective: We performed this prospective study to identify both the incidence of adrenal insufficiency (AI) and health-related quality of life (HRQOL) in advanced gastric cancer (AGC) patients who were treated with the S-1 plus cisplatin (SP) regimen as a first-line palliative chemotherapy. Methods: We assessed adverse events (AEs) observed in 52 patients who received the SP regimen for AGC between January 2009 and June 2010 using the Common Toxicity Criteria Adverse Events (CTCAE) version 3.0. Adrenal function was assessed at baseline and 12 weeks after chemotherapy using the low-dose adrenocorticotropic hormone stimulation test. HRQOL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 (EORTC-QLQ C30). Results: The incidence of AI was 30.8{\%} (n = 16) and of AE observed 55{\%} (n = 29) among 52 patients after 12 weeks of chemotherapy. Of 29 patients with AE, 34.4{\%} (n = 10) were diagnosed with AI, and of 23 patients without AE, 26.1{\%} (n = 6) were diagnosed with AI. Conclusion: The incidence of secondary AI in AGC patients was not rare and was not correlated with the presence of nonspecific AEs. Although patients diagnosed with AI did not show any related symptoms, they are at risk of potentially life-threatening consequences. Thus, the evaluation of AI could be suggested for patients who received chemotherapy.",
author = "Kim, {Hye Ryun} and Kim, {Jee Hung} and Yumie Rhee and Hosun Lee and Song, {Seung Eun} and Chan Kim and Sukyung Song and Noh, {Sung Hoon} and SunYoung Rha",
year = "2016",
month = "5",
day = "1",
doi = "10.1159/000445010",
language = "English",
volume = "90",
pages = "248--254",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "5",

}

Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy. / Kim, Hye Ryun; Kim, Jee Hung; Rhee, Yumie; Lee, Hosun; Song, Seung Eun; Kim, Chan; Song, Sukyung; Noh, Sung Hoon; Rha, SunYoung.

In: Oncology (Switzerland), Vol. 90, No. 5, 01.05.2016, p. 248-254.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy

AU - Kim, Hye Ryun

AU - Kim, Jee Hung

AU - Rhee, Yumie

AU - Lee, Hosun

AU - Song, Seung Eun

AU - Kim, Chan

AU - Song, Sukyung

AU - Noh, Sung Hoon

AU - Rha, SunYoung

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Objective: We performed this prospective study to identify both the incidence of adrenal insufficiency (AI) and health-related quality of life (HRQOL) in advanced gastric cancer (AGC) patients who were treated with the S-1 plus cisplatin (SP) regimen as a first-line palliative chemotherapy. Methods: We assessed adverse events (AEs) observed in 52 patients who received the SP regimen for AGC between January 2009 and June 2010 using the Common Toxicity Criteria Adverse Events (CTCAE) version 3.0. Adrenal function was assessed at baseline and 12 weeks after chemotherapy using the low-dose adrenocorticotropic hormone stimulation test. HRQOL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 (EORTC-QLQ C30). Results: The incidence of AI was 30.8% (n = 16) and of AE observed 55% (n = 29) among 52 patients after 12 weeks of chemotherapy. Of 29 patients with AE, 34.4% (n = 10) were diagnosed with AI, and of 23 patients without AE, 26.1% (n = 6) were diagnosed with AI. Conclusion: The incidence of secondary AI in AGC patients was not rare and was not correlated with the presence of nonspecific AEs. Although patients diagnosed with AI did not show any related symptoms, they are at risk of potentially life-threatening consequences. Thus, the evaluation of AI could be suggested for patients who received chemotherapy.

AB - Objective: We performed this prospective study to identify both the incidence of adrenal insufficiency (AI) and health-related quality of life (HRQOL) in advanced gastric cancer (AGC) patients who were treated with the S-1 plus cisplatin (SP) regimen as a first-line palliative chemotherapy. Methods: We assessed adverse events (AEs) observed in 52 patients who received the SP regimen for AGC between January 2009 and June 2010 using the Common Toxicity Criteria Adverse Events (CTCAE) version 3.0. Adrenal function was assessed at baseline and 12 weeks after chemotherapy using the low-dose adrenocorticotropic hormone stimulation test. HRQOL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 (EORTC-QLQ C30). Results: The incidence of AI was 30.8% (n = 16) and of AE observed 55% (n = 29) among 52 patients after 12 weeks of chemotherapy. Of 29 patients with AE, 34.4% (n = 10) were diagnosed with AI, and of 23 patients without AE, 26.1% (n = 6) were diagnosed with AI. Conclusion: The incidence of secondary AI in AGC patients was not rare and was not correlated with the presence of nonspecific AEs. Although patients diagnosed with AI did not show any related symptoms, they are at risk of potentially life-threatening consequences. Thus, the evaluation of AI could be suggested for patients who received chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84963610070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963610070&partnerID=8YFLogxK

U2 - 10.1159/000445010

DO - 10.1159/000445010

M3 - Article

C2 - 27070835

AN - SCOPUS:84963610070

VL - 90

SP - 248

EP - 254

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5

ER -